153 related articles for article (PubMed ID: 36281720)
21. Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis.
Wang S; Wu T; Zuo Z; Jin P; Luo X; Deng M
Eur J Prev Cardiol; 2022 Jan; 28(16):1840-1849. PubMed ID: 34136913
[TBL] [Abstract][Full Text] [Related]
22. Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus.
Choi Y; Ko SH; Chang K; Yoo KD; Ihm SH
J Diabetes; 2023 Nov; 15(11):944-954. PubMed ID: 37528628
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin.
Fernandes G; Matos JE; Jaffe DH; Beyer G; Yang L; Iglay K; Gantz I; Rajpathak S
Curr Med Res Opin; 2020 Mar; 36(3):377-386. PubMed ID: 31771370
[No Abstract] [Full Text] [Related]
24. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
[TBL] [Abstract][Full Text] [Related]
25. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
26. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
27. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
Nishimura R; Kato H; Kisanuki K; Oh A; Hiroi S; Onishi Y; Guelfucci F; Shimasaki Y
BMJ Open; 2019 Mar; 9(3):e025806. PubMed ID: 30826768
[TBL] [Abstract][Full Text] [Related]
30. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
31. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
[TBL] [Abstract][Full Text] [Related]
32. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
33. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
34. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
Rathmann W; Kostev K
J Diabetes Complications; 2017 Apr; 31(4):687-692. PubMed ID: 28169131
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
Xu S; Zhang X; Tang L; Zhang F; Tong N
Postgrad Med; 2017 Mar; 129(2):205-215. PubMed ID: 27813442
[TBL] [Abstract][Full Text] [Related]
36. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
38. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
39. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in the Inpatient Setting.
Petite SE; Hill MC
J Pharm Pract; 2022 Apr; 35(2):229-234. PubMed ID: 33094657
[TBL] [Abstract][Full Text] [Related]
40. Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
Chen HH; Lin CL; Yeh SY; Kao CH
QJM; 2016 Feb; 109(2):91-5. PubMed ID: 25991869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
